Annals of Oncology 26 (Supplement 6): vi114–vi122, 2015
doi:10.1093/annonc/mdv346.16
Session N. Simultaneous care
N16
GelX Oral Gel and GelX Oral Spray (GOG&GOS) pain relief for
oral mucositis
abstracts
Oral Mucositis (OM) is a painful condition affecting the mucosa of the mouth and
throat.OM refers specifically to toxicity associated with chemotherapy and radiation
therapy for cancer. Approximately 40% of pz receiving chemotherapy as part of their
cancer treatment will develop some degree of Mucositis. The process of oral mucositis
involves not only the epithelium, but also includes multiple cellular processes of the
lamina propria and sub-mucosa. Inflammation is a complex biological event; a loss of
mineral homeostasis contributes to the destructive effects of this process. Current
treatment for OM is largely palliative and no adequate treatment with conclusive
evidence exists.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com
Downloaded from https://academic.oup.com/annonc/article-abstract/26/suppl_6/vi/216627 by guest on 26 August 2019
F. Zannier1, P. Belloni2, D. Toniolo2, C. Cozzi2
1
A.O. G. Salvini, Rho
2
A.O. G. Salvini, Rho
GOG&GOS are novel muco-protecting products utilizing the bioactive Zinc-Taurine
complex, designed to resolve the underlying inflammatory signaling pathways that
cause OM while providing anti-bacterial, anti-fungal and analgesic relief for patients
with OM. Zinc and Taurine exert anti-microbial, anti-inflammatory, free radical
scavenging and analgesic effects when topically applied; Zinc-Taurine complex
demonstrated enhanced biological activity compared to its individual components.
GOG&GOS are viscous products in two different delivery systems (rinse and spray)
designed to coat the oral cavity with a film-like barrier which protects and insulates
against stimulants capable of causing mouth pain and irritation. This study wants to
assess the ability of GOG&GOS to delay the onset of OM, reduce pain and severity of
oral mucositis and decrease the time to resolution of OM. We evaluated 40 pz with
solid tumors and who underwent cisplatinum/5FU containing chemotherapy,
chemo-radiation therapy and radiation therapy . Each patient utilized: GOG as
prevention 2 times per day ten days before starting cancer treatment; GOS as therapy 3
times per day during cancer treatment. OM were evaluated by physician and pz using
RTOG scale at the beginning of prevention, after one month of treatment, at the end of
treatment, one month after the end of treatment. After 1 month from the end of
treatment 30 pz had completely resolution of pain and swelling alteration; 8 pz no pain
but loss of swelling, 2 pz had mild pain and loss of swelling. GOG&GOS is safe and
active and could be new approach in management and prevention of OM. Phase III
study is ongoing vs preference physicians therapy.